Pay in 4 interest-free payments of $7.12 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Clinical trial data submitted to the MHRA and EMA document headache as common (affecting 1 in 10 to 1 in 100 people) with diabetes formulations, and very common (more than 1 in 10) with higher weight-management doses
Russell-Jones D, Cuddihy RM, Hanefeld M, Kumar A, Gonzlez JG, et al
Abstract This large community-based cohort study investigates the impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), specifically Liraglutide and Semaglutide, on the risk of developing psychiatric conditions such as depression, anxiety, and suicidal behaviors in patients with obesity
PMID 28203348
Evidence shows that semaglutide can help lower the risk of heart disease possibly through its beneficial effects on obesity, blood sugar, and blood pressure: Wegovy, Ozempic, and Rybelsus are all medications that contain the active ingredient semaglutide, but they have different approved uses and formulations
10.1056/NEJMoa2025845 178
US$ 23.64
US$ 23.53
US$ 21.64
US$ 26.39
